These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21975382)

  • 1. Potential role of FDG PET imaging in predicting metastatic potential and assessment of therapeutic response to neoadjuvant chemotherapy in Ewing sarcoma family of tumors.
    Gupta K; Pawaskar A; Basu S; Rajan MG; Asopa RV; Arora B; Nair N; Banavali S
    Clin Nucl Med; 2011 Nov; 36(11):973-7. PubMed ID: 21975382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different
    El-Hennawy G; Moustafa H; Omar W; Elkinaai N; Kamel A; Zaki I; Farid N; El-Kholy E
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28605. PubMed ID: 32706520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.
    Raciborska A; Bilska K; Drabko K; Michalak E; Chaber R; Pogorzała M; Połczyńska K; Sobol G; Wieczorek M; Muszyńska-Rosłan K; Rychlowska-Pruszyńska M; Rodriguez-Galindo C; Dziuk M
    Clin Transl Oncol; 2016 Feb; 18(2):189-95. PubMed ID: 26250765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
    Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
    Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
    Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
    Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
    Gaston LL; Di Bella C; Slavin J; Hicks RJ; Choong PF
    Skeletal Radiol; 2011 Aug; 40(8):1007-15. PubMed ID: 21298431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor.
    Hyun O J; Luber BS; Leal JP; Wang H; Bolejack V; Schuetze SM; Schwartz LH; Helman LJ; Reinke D; Baker LH; Wahl RL
    J Nucl Med; 2016 May; 57(5):735-40. PubMed ID: 26795289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.
    Bailly C; Leforestier R; Campion L; Thebaud E; Moreau A; Kraeber-Bodere F; Carlier T; Bodet-Milin C
    PLoS One; 2017; 12(8):e0183841. PubMed ID: 28841702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.
    Eary JF; Conrad EU; O'Sullivan J; Hawkins DS; Schuetze SM; O'Sullivan F
    J Bone Joint Surg Am; 2014 Jan; 96(2):152-8. PubMed ID: 24430415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
    Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
    J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.
    Denecke T; Hundsdörfer P; Misch D; Steffen IG; Schönberger S; Furth C; Plotkin M; Ruf J; Hautzel H; Stöver B; Kluge R; Bierbach U; Otto S; Beck JF; Franzius C; Henze G; Amthauer H
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1842-53. PubMed ID: 20505933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.
    Hwang JP; Lim I; Kong CB; Jeon DG; Byun BH; Kim BI; Choi CW; Lim SM
    PLoS One; 2016; 11(4):e0153281. PubMed ID: 27100297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Accuracy of 18F-FDG PET/CT in the Staging and Assessment of Response to Chemotherapy in Children With Ewing Sarcoma.
    Ruggiero A; Lanni V; Librizzi A; Maurizi P; Attinà G; Mastrangelo S; Giordano A; Riccardi R
    J Pediatr Hematol Oncol; 2018 May; 40(4):277-284. PubMed ID: 29620679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
    Hawkins DS; Rajendran JG; Conrad EU; Bruckner JD; Eary JF
    Cancer; 2002 Jun; 94(12):3277-84. PubMed ID: 12115361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
    Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
    Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soft Tissue Sarcoma Response to Two Cycles of Neoadjuvant Chemotherapy: A Multireader Analysis of MRI Findings and Agreement with RECIST Criteria and Change in SUVmax.
    Favinger JL; Hippe DS; Davidson DJ; Elojeimy S; Roth ES; Lindberg AW; Ha AS
    Acad Radiol; 2018 Apr; 25(4):470-475. PubMed ID: 29273189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].
    Bestic JM; Peterson JJ; Bancroft LW
    Radiographics; 2009; 29(5):1487-500. PubMed ID: 19755607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.